Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella, Inc. a subsidiary of Immix Biopharma, Inc. (NASDAQ:IMMX)
Format
JPEG
Quelle:
Immix Biopharma, Inc.